<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:8pt Arial, sans-serif; }
 .font1 { font:10pt Arial, sans-serif; }
 .font2 { font:22pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font1" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font2">J.P. Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">Table 11: Continuous investment internationally</span></p>
<p><span class="font1">International Investments ofFosun pharmaceutical in 2015</span></p>
<table border="1">
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">R&amp;D</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Ambrx</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">Fosun Pharma, HOPU Investments, China Everbright Limited and WuXi PharmaTech jointly acquired Ambrx<sub>r</sub> aclinical-stage biotechnology company focused on discovering and developing optimized protein therapeutics with cutting edge site-specitic bio-conjugates technology platform</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Amerigen</span></p></td><td style="vertical-align:top;">
<p><span class="font1">In Jan 2015, acquired additional class A-1 preference shares represening approximately 24.1% of the total share capital of AMG, a U.S. developer and manufacturer of oral sustained-release and controlled-release generic drug</span></p></td></tr>
<tr><td rowspan="3" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Personalized</span></p>
<p><span class="font0" style="font-weight:bold;">Diagnosis</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Genefirst</span></p></td><td style="vertical-align:top;">
<p><span class="font1">In Jan 2015, acquired approximately 35.23% equity interest in Genefirst Limited, a U.K. company principally engaged in developing and manufacturing molecular diagnostic products for infectious diseases and cancer</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Saladax</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Invested in approximately 20% equity interest in Saladax Biomedical, Inc., a U.S. company which is principally engaged in personalized medicine dose diagnostic tests</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Miacom diagnostics</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Invested in approximately 37% equity interest in miacom Dagnosfics GmbH, a German enterprise principally engaged in developing low-cost, efficient and convenient in-vitro diagnostic reagents</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Novel Medical</span></p>
<p><span class="font0" style="font-weight:bold;">devices</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Scanadu</span></p></td><td style="vertical-align:top;">
<p><span class="font1">A Silicon Valley based medtech company that is building a family of mobile medical products for consumers. B-round tunding was led by Fosun Pharma and Tencent Holdings Limited, Fosun Pharma acquired approximately 4.76% equity interest for USD5million.</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Check cap</span></p></td><td style="vertical-align:top;">
<p><span class="font1">In Feb 2015, invested in a 6.18% equity interest in Check-cap, developer of the world’s first preparation-free, non-invasive, high-resolution imaging system for colorectal cancer screening</span></p></td></tr>
<tr><td rowspan="2" style="vertical-align:middle;">
<p><span class="font0" style="font-weight:bold;">Internet</span></p>
<p><span class="font0" style="font-weight:bold;">Healthcare</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">Guahao.com</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Acquired 9.73% equity interest in Guahao.com accumulatively in 2015 and set up strategic cooperation with the company</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">Mingy izhudao</span></p></td><td style="vertical-align:top;">
<p><span class="font1">Invested RMB36 million in Mingyizhudao as a lead investor for its A-round financing for 15% of its equity interest in October 2015</span></p></td></tr>
</table>
<p><span class="font1">Source: Company data, J.P. Morgan</span></p>
<p><span class="font1">16</span></p>
</body>
</html>